Luspatercept and Lenalidomide (L2)
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 50 patients (estimated)
- Sponsors
- University of Miami
- Collaborators
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, Bristol Myers Squibb
- Tags
- Erythroid Maturation Agent (EMA), Immunomodulatory Drug (IMiD), Red Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1604
- NCT Identifier
- NCT04539236
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.